Premium
Endocrine and metabolic indices during administration of a lipophilic bis‐phenol, probucol
Author(s) -
Danowski T. S.,
Vester J. W.,
Sunder J. H.,
Gonzalez A. R.,
Khurana R. C.,
Jung Y.
Publication year - 1971
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1971126929
Subject(s) - endocrinology , medicine , probucol , creatinine , metyrapone , chemistry , hormone , cholesterol
The administration of a cholesterol‐lowering drug, 4,4‐(isopropylidenedithio) bis(2,6‐di‐tbutylphenol), probucol (DH‐581) at a dosage of 1,000 mg. per day for 6 months, usually did not affect other serum solutes, serum enzymes, hepatic indices, tests of thyroid function, plasma 11(OH)‐corticosferoids (including diurnal variation, dexamethasone suppression, and ACTH stimulation effects), urinary creatinine, creatinine clearance, 17‐ketosteroids, Porter‐Silber chromogens, 11‐desoxycortisol metabolites, the responses of urinary steroids to metyrapone, glucose tolerance tests, insulin and growth hormone responses to oral carbohydrate, hematologic indices including eosinophil counts in peripheral blood, or electrocardiographic tracings. Serum total cholesterol decreased in the ma;ority of the patients, but serum total triglycerides were usually unaffected. Minor changes in serum CO 2 , aldolase, and growth hormone were recorded in some of the treatment periods, but final values were still within the normal range.